|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||15.60 - 18.08|
|52 Week Range||11.50 - 69.02|
|Beta (3Y Monthly)||2.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.70|
Clovis Oncology, Inc. (CLVS) announced today that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations. “We have multiple families of patents protecting Rubraca in the U.S., including composition of matter, salts/polymorphs, dosage forms and formulations, and methods of use, and we continue to add new patents, including this high dosage strength method of treatment patent,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian, metastatic castration-resistant prostate, and bladder cancers, as monotherapy, and in combination with other anti-cancer agents.
Of the nine Colorado companies on the list, five are software companies and two are in biotech or pharmaceuticals.
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
While Clovis received an income tax benefit of $1.23 million in the third quarter of 2017, it incurred an income tax expense of $13,000 in the third quarter of 2018. Clovis Oncology had a net income of -$90.37 million in the third quarter compared to -$59.06 million in the third quarter of 2017. Clovis Oncology’s net EPS were $1.24 in the third quarter of 2017.
For 2018 and 2019, Clovis Oncology (CLVS) is expected to generate revenues of $88.79 million and $165.13 million, respectively, compared to its revenue of $55.51 million in 2017.
Clovis Oncology (CLVS) is focused on bringing to market innovative anticancer agents. One of its products, Rubraca, has been approved for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. In July, Clovis received EMA (European Medicines Agency) approval for its application for a variation to its marketing authorization of Rubraca.
Clovis Oncology (CLVS) incurred selling, general, and administrative expenses of $42.49 million in the third quarter compared to $35.01 million in the third quarter of 2017. This increase was due to higher commercialization activities for Rubraca and preparation for its expected launch in Europe.
PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.
AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%. On November 8, Portola Pharmaceuticals stock price closed at $23.14, which was ~21.41% growth from its previous close of $19.06. On November 7, Portola Pharmaceuticals stock price closed at $19.06, which was ~2.80% growth from its previous close of $18.54. On November 7, the company hit its 52-week low of $18.18.
Clovis Oncology, Inc. today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 11:30 AM Mountain Time.
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
HENDERSON, NV / ACCESSWIRE / November 6, 2018 / Big biotech stock buybacks "have destroyed more than $12 billion in value, and generated no positive return in total, at least as a portfolio investment," ...
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Strongbridge Biopharma was one of the biggest winners in the biotech arena yesterday after announcing a deal with Denmark’s Novo Nordisk. Shares of Clovis Oncology were in the red after reporting third quarter results. Strongbridge Biopharma plc shares closed up 58.02% yesterday on about 11.6 million shares traded compared to an average trading volume of around 575,000 shares.
Yes, the market looks set to rise for a second consecutive day, but some strategists still see risks.
Clovis (CLVS) misses estimates in the third quarter for both earnings and sales and guides lower sales for only marketed drug, Rubraca in Q4. Shares decline.
Clovis (CLVS) delivered earnings and revenue surprises of -6.88% and -24.46%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Shares of Clovis Oncology Inc. tanked more than 22% in the extended session Tuesday after the Boulder, Colo.,-based biopharma company reported a wider-than-expected third-quarter loss and quarterly sales missed expectations. Clovis said it lost $89.9 million, or $1.71 a share, in the quarter, compared with a loss of $61 million, or $1.24 a share, in the third quarter of 2017. Revenue rose to $23 million from $17 million a year ago. Analysts polled by FactSet had expected a loss of $1.59 a share on sales of $30 million for the quarter. Clovis shares ended the regular trading day down 0.5%.
On a per-share basis, the Boulder, Colorado-based company said it had a loss of $1.71. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...